Stent developer ITGI Medical Ltd. (TASE:ITGI) reports success in the initial series of implants of its AneuGraft stent in patients suffering from acute myocardial ischemia, a lack of blood flow to the heart.
The stents were inserted in Sheffield, UK, and included six months subsequent monitoring of the stents, which were found to provide an additional medical response for heart attacks.
ITGI said that prevailing medical practice for clearing blocked arteries involved the vacuuming of blood clots, but that the clots sometimes remained stuck to the artery walls, which risked the clots entering the bloodstream.
In all cases in which the AneuGraft was implanted by catheterization following the removal of the blood clots, the stent trapped the clots that remained on the artery wall, thereby preventing them from causing blockages elsewhere in the body. In these cases, the Aneugraft also functioned as an embolic protection device to prevent clots from entering the bloodstream.
ITGI's share price 0.2% by midday to NIS 0.59, giving a market cap of NIS 46 million. The share price rose 4% yesterday.
Published by Globes [online], Israel business news - www.globes-online.com - on December 29, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010